The 340B Drug Discount Program is an essential source of support for Community Health Centers, allowing them to stretch increasingly scarce federal resources and reinvest in patient care. Health centers report that 340B is integral to their ability to provide high quality, cost-effective care to their patients. This translates to better patient care in any variety of ways, be it through improved pharmacy access, extended health center hours, or the ability to provide additional providers or services.
Recent 340B Developments on Capitol Hill
On March 24, 2015, the House Energy and Commerce Subcommittee on Health held a hearing entitled “Examining the 340B Drug Pricing Program.” The Subcommittee heard testimony from the Health Resources and Services Administration (HRSA), the Government Accountability Office (GAO), and the Department of Health and Human Services Office of the Inspector General (OIG). The stated purpose of the hearing was to “review the functionality of the program to ensure its goal of improving access to prescription drugs for needy patients serving these populations.” Fourteen Members of Congress participated, many of whom expressed broad support for the 340B program, and specifically for health center participation in the program. Several Members also emphasized the need for improved transparency and accountability. NACHC attended the hearing and submitted a statement for the record. Supporting materials, including witness testimony and a background memo, are available on the Energy and Commerce Committee website, as is a link to watch a recording of the full hearing.
NACHC works with a variety of stakeholder organizations to protect and improve the 340B Drug Discount Pricing Program. To learn more about some of this work, please visit the 340B Coalition website.
NACHC Fact Sheets